// App-Quantinova.ai

BSH2020‐OR‐023 : ELEVATE‐TN: a phase 3, multicentre, open‐label study of acalabrutinib (Ab) combined with obinutuzumab (O) or Ab alone versus O plus chlorambucil (Clb) in patients (pts) with treatment‐naive chronic lymphocytic leukaemia (TN‐CLL)

Researchers

Presenter

  • T. Munir

Principal Investigators

  • V. Banerji

  • L. M. Fogliatto

  • Y. Herishanu

  • R. Walewska

  • G. Follows

  • K. Karlsson

  • P. Ghia

  • G. Corbett

  • P. Walker

  • M. Egyed

  • W. Jurczak

  • G. Salles

  • A. Janssens

  • F. Cymbalista

  • W. Wierda

  • S. Coutre

  • J. M. Pagel

  • A. P. Skarbnik

  • M. Kamdar

  • J. A. Woyach

  • R. Izumi

  • V. Munugalavadla

  • P. Patel

  • M. H. Wang

  • S. Wong

  • J. C. Byrd

Medical Centers

  • Haematology, Haematological Malignancy Diagnostic Service (HMDS), St. James's Institute of Oncology, Leeds, UK

  • Willamette Valley Cancer Institute and Research Center, Springfield, OR

  • Department of Internal Medicine, Biochemistry & Medical Genetics, CancerCare Manitoba Foundation, Winnipeg, Canada

  • PPGBM - Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

  • Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel

  • Royal Bournemouth Hospital, Bournemouth, United Kingdom

  • Addenbrooke's Hospital NHS Trust, Cambridge, UK

  • Lund University Hospital, Lund, Sweden

  • Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

  • Tauranga Hospital, Tauranga, New Zealand

  • Alfred Health-Monash University, Melbourne, Australia

  • Somogy County Mór Kaposi General Hospital, Kaposvár, Hungary

  • Jagiellonian University Medical College, Cracow, Poland

  • Hospices civils de Lyon, centre hospitalier Lyon Sud, Pierre‐Bénite, France

  • CHU Avicenne, Bobigny, France

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Stanford School of Medicine, Stanford, CA

  • Swedish Cancer Institute, Center for Blood Disorders and Stem Cell Transplantation,Seattle, WA,Stati Uniti

  • Division of Lymphoma and Chronic Lymphocytic Leukemia,Novant Health,Charlotte,United States

  • University of Colorado Cancer Center, Aurora, CO

  • The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • Acerta Pharma, South San Francisco, CA

Locations

  • United Kingdom

  • United States

  • Canada

  • Brazil

  • Israel

  • Sweden

  • Italy

  • New Zealand

  • Australia

  • Hungary

  • Poland

  • France

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • Creatinine

Drug/Treatment

  • ACP-196

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • chlorambucil

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

  • Multicenteric

Phase

  • III

Study Id's

  • NCT02475681

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved